Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase III study of denosumab in MM meets primary enpoint

Oct. 24, 2016

Merck & Co.'s KEYNOTE-045 study meets primary endpoint

Oct. 24, 2016

Advaxis begins part B of KEYNOTE-046 trial

Oct. 21, 2016

NBE Therapeutics and SOTIO to develop next-generation ADCs

Oct. 21, 2016

CFDA accepts CStone Pharmaceuticals' IND for anti-PD-L1 monoclonal antibody

Oct. 21, 2016

FDA grants accelerated approval for Lartruvo in soft tissue sarcoma

Oct. 20, 2016

Advanced Proteome Therapeutics acquires option to antibody candidates from University of Toronto

Oct. 20, 2016

FDA approves Tecentriq for metastatic NSCLC

Oct. 19, 2016

Leukemia & Lymphoma Society announce launch of Beat AML Master Trial

Oct. 19, 2016

Adaptimmune Therapeutics initiates phase I study of T-cell therapy in urothelial cancer

Oct. 19, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...